LAVAL, Quebec, Sept. 2, 2010 (GLOBE NEWSWIRE) -- Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. (“Neptune”) (Nasdaq:NEPT) (TSX-V:NTB) reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre™ on C-reactive protein (CRP) levels, a biomarker of CardioVascular Disease risk (CVD) and associated with diabetes and obesity.
